2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences

March 1, 2024 at 7:00 AM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 1, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET.

Members of the management team will also be presenting at the following upcoming investor conferences:

  • TD Cowen 44th Annual Healthcare Conference in Boston, MA on Wednesday, March 6, 2024 at 2:10 p.m. ET
  • Leerink Partners Global Biopharma Conference in Miami, FL on Wednesday, March 13 at 8:00 a.m. ET

Live webcasts of the investor conference presentations will be available via the Investors and Media section of 2seventy bio’s website at https://ir.2seventybio.com/. Replays will be archived on 2seventy bio’s site for 30 days following the event.

Earnings Call Information

2seventy bio will host a conference call and live webcast on March 5, at 8:00 a.m. ET to discuss fourth quarter 2023 / full year 2023 financial results and recent business highlights. To join the live conference call, please register at: https://register.vevent.com/register/BI1f96356c45184868a0cde91b2864ffd8. Upon registering, each participant will be provided with call details and access codes. The live webcast may be accessed by visiting the event link at: https://edge.media-server.com/mmc/p/3ob85kez/.

A replay of the webcast may be accessed from the “News and Events” page in the Investors and Media section of the Company’s website at https://ir.2seventybio.com/ and will be available for 30 days following the event.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma. We are focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: X (formerly Twitter) and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

Elizabeth Pingpank Hickin, 860-463-0469

Jenn Snyder, 617-448-0281

Source: 2seventy bio, Inc.